ES2054860T5 - Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos. - Google Patents

Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.

Info

Publication number
ES2054860T5
ES2054860T5 ES88730162T ES88730162T ES2054860T5 ES 2054860 T5 ES2054860 T5 ES 2054860T5 ES 88730162 T ES88730162 T ES 88730162T ES 88730162 T ES88730162 T ES 88730162T ES 2054860 T5 ES2054860 T5 ES 2054860T5
Authority
ES
Spain
Prior art keywords
halogen
derivatives
prostaglandinas
medications
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88730162T
Other languages
English (en)
Other versions
ES2054860T3 (es
Inventor
Bernd Dr Buchmann
Werner Dr Skuballa
Helmut Prof Dr Vorbruggen
Bernd Dr Raduchel
Olaf Dr Loge
Walter Dr Elger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25857817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2054860(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19873724190 external-priority patent/DE3724190A1/de
Priority claimed from DE19873724189 external-priority patent/DE3724189A1/de
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2054860T3 publication Critical patent/ES2054860T3/es
Publication of ES2054860T5 publication Critical patent/ES2054860T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A DERIVADOS 9-HALOGENO(Z)-PROSTAGLANDINA DE FORMULA (I) DONDE LOS SUSTITUYENTES TIENEN EL SIGNIFICADO QUE SE DETALLA EN LA INVENCION, SUS SALES Y SUS CICLODEXTRICLARATOS Y SU APLICACION FARMACEUTICA.
ES88730162T 1987-07-17 1988-07-15 Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos. Expired - Lifetime ES2054860T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873724190 DE3724190A1 (de) 1987-07-17 1987-07-17 9-halogen-3-oxa-(z)-(delta)(pfeil hoch)5(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE19873724189 DE3724189A1 (de) 1987-07-17 1987-07-17 9-halogen-(z)-(delta)(pfeil hoch)4(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
ES2054860T3 ES2054860T3 (es) 1994-08-16
ES2054860T5 true ES2054860T5 (es) 2003-11-01

Family

ID=25857817

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88730162T Expired - Lifetime ES2054860T5 (es) 1987-07-17 1988-07-15 Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.

Country Status (12)

Country Link
US (1) US6225347B1 (es)
EP (1) EP0299914B2 (es)
JP (1) JP2716986B2 (es)
CA (1) CA1322197C (es)
DE (1) DE3880034D1 (es)
DK (1) DK170889B1 (es)
ES (1) ES2054860T5 (es)
HU (1) HU206084B (es)
IE (1) IE62483B1 (es)
IL (1) IL87116A (es)
NZ (1) NZ225436A (es)
WO (1) WO1989000559A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3923797A1 (de) * 1989-07-14 1991-01-24 Schering Ag 9-fluor-prostaglandin-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE4008925A1 (de) * 1990-03-16 1991-09-19 Schering Ag 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
DE4024347A1 (de) * 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE4036140A1 (de) * 1990-11-09 1992-05-14 Schering Ag 9-halogen-11ss-hydroxy-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CA2140853A1 (en) * 1992-07-24 1994-02-03 Takehiro Amano Prostaglandin derivatives
DE4229050A1 (de) * 1992-08-31 1994-03-03 Schering Ag Neue 9-Chlor-Prostaglandin-Ester und -amide
DE4229048A1 (de) * 1992-08-31 1994-03-03 Schering Ag Ester von 9-Chlor-Prostaglandinen, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
JPH08500597A (ja) * 1992-08-31 1996-01-23 シエーリング アクチエンゲゼルシヤフト ９−クロル−プロスタグランジン−エステルおよび９−クロル−プロスタグランジンアミド並びに医薬品の製造のための該９−クロル−プロスタグランジン−エステルおよび９−クロル−プロスタグランジンアミドの使用
AU674038B2 (en) * 1992-10-13 1996-12-05 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
KR950703527A (ko) * 1992-10-20 1995-09-20 후미에 사토 프로스타글란딘 유도체
US5721273A (en) 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
US5627209A (en) * 1993-12-15 1997-05-06 Alcon Laboratories, Inc. Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
CA2237898A1 (en) * 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US5700835A (en) * 1995-12-22 1997-12-23 Alcon Laboratories, Inc. 3-Oxa-D-prostaglandins for lowering IOP
US5599838A (en) * 1996-02-23 1997-02-04 Taisho Pharmaceutical Co., Ltd. Prostaglandin derivatives
AU5439398A (en) 1996-11-12 1998-06-03 Alcon Laboratories, Inc. Cis-delta4 analogs of prostaglandins as ocular hypotensives
US6015922A (en) * 1997-12-19 2000-01-18 Alcon Laboratories, Inc. N-alkyl-N-alkoxycarboxamides and methods of use in prostaglandin synthesis
US6740679B1 (en) * 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US20030162833A1 (en) * 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
CA2382265A1 (en) 1999-08-13 2001-02-22 Taisho Pharmaceutical Co., Ltd. Prostaglandin derivatives
ATE455098T1 (de) 1999-09-10 2010-01-15 Taisho Pharmaceutical Co Ltd Prostaglandin-derivate
GB0012249D0 (en) * 2000-05-19 2000-07-12 Chirotech Technology Ltd Process for the preparation of 11-oxaprostaglandins
US20040266880A1 (en) * 2002-02-22 2004-12-30 Fumie Sato Antipruritics
MXPA04004371A (es) * 2002-08-09 2004-08-13 Taisho Pharmaceutical Co Ltd Agente antipruritico.
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
AU2003301900A1 (en) * 2002-11-13 2004-06-03 Fumie Sato Antipruritic drug
WO2006014353A2 (en) 2004-07-02 2006-02-09 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
ES2614090T3 (es) 2005-12-29 2017-05-29 Celtaxsys, Inc. Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa
MX2009003876A (es) 2006-10-12 2009-05-11 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos.
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
PL2350090T3 (pl) * 2008-10-17 2015-11-30 Xenon Pharmaceuticals Inc Związki spiro-oksindolowe i ich zastosowanie jako środków terapeutycznych
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
PE20170202A1 (es) * 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
EP2538919B1 (en) 2010-02-26 2017-07-12 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
CA2869547A1 (en) 2012-04-12 2013-10-17 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
RU2696559C2 (ru) 2013-03-14 2019-08-05 Селтакссис, Инк. Ингибиторы лейкотриен а4-гидролазы
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
EP3551611A1 (en) 2016-12-09 2019-10-16 Celtaxsys Inc. Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase
RU2019119652A (ru) 2016-12-09 2021-01-11 Селтакссис, Инк. Ингибиторы лейкотриен-а4-гидролазы
CA3045887A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754114A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux composes de la classe des prostaglandines et leur procede de preparation
US3936487A (en) 1970-06-17 1976-02-03 The Upjohn Company 3-Oxa prostaglandin Fα-type compounds
US3954835A (en) 1972-04-27 1976-05-04 The Upjohn Company 4,5-Cis-didehydro-PGF1 compounds
US3980694A (en) 1974-04-11 1976-09-14 The Upjohn Company 4-Oxa phenyl-substituted PGA compounds
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE2950027A1 (de) * 1979-12-10 1981-06-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin 9-chlor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel
DE3048906A1 (de) 1980-12-19 1982-07-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3126924A1 (de) 1981-07-03 1983-01-20 Schering Ag, 1000 Berlin Und 4619 Bergkamen 9-fluor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel
US4579958A (en) 1983-12-23 1986-04-01 G. D. Searle & Co. 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds
US4971987A (en) * 1984-07-27 1990-11-20 Schering Aktiengesellschaft New carbacycline, process for their production and their use as a drug
DE3510978A1 (de) * 1985-03-22 1986-09-25 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CA2140853A1 (en) 1992-07-24 1994-02-03 Takehiro Amano Prostaglandin derivatives

Also Published As

Publication number Publication date
DK132789D0 (da) 1989-03-17
EP0299914B1 (de) 1993-04-07
JP2716986B2 (ja) 1998-02-18
HU206084B (en) 1992-08-28
IE62483B1 (en) 1995-02-08
EP0299914B2 (de) 2003-04-23
DE3880034D1 (de) 1993-05-13
US6225347B1 (en) 2001-05-01
DK132789A (da) 1989-03-17
DK170889B1 (da) 1996-03-04
HUT51222A (en) 1990-04-28
IL87116A0 (en) 1988-12-30
NZ225436A (en) 1991-04-26
IL87116A (en) 1993-03-15
CA1322197C (en) 1993-09-14
JPH02502009A (ja) 1990-07-05
WO1989000559A1 (en) 1989-01-26
IE882189L (en) 1989-01-17
EP0299914A1 (de) 1989-01-18
ES2054860T3 (es) 1994-08-16

Similar Documents

Publication Publication Date Title
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2053778T3 (es) Procedimiento para la obtencion de derivados del tiazol.
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
ES2037243T3 (es) Tiazolidindionas como agentes hipoglicemicos y anti-ateroscleroticos.
AR023401A1 (es) Derivados de 1,4-benzotiazepina-1,1-dioxido sustituidos con restos de azucar, procedimientos para su preparacion, medicamentos que contienen estoscompuestos, y su empleo para preparar un medicamento
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2075202T3 (es) Nuevas arilpiridazinas, su preparacion, su utilizacion, y medicamentos que las contienen.
PT83647B (pt) Processo para a preparacao de novos derivados de benzimidazole com actividade farmacologica e de composicoes farmaceuticas que os contem
ES2032394T3 (es) Procedimiento para preparar derivados de tienoimidazol sustituidos.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
ES2043863T3 (es) Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina.
ES2073393T3 (es) Derivados de acidos 2,4- y 2,5-dicarboxilicos, procedimiento para su preparacion, utilizacion de los mismos asi como medicamentos a base de estos compuestos.
ES2143833T3 (es) Acidos y esteres de la diosmetina y composiciones farmaceuticas que los contienen.
ES2062997T3 (es) Vinilcefalosporinas sustituidas, procedimiento para su fabricacion y su uso como medicamento.
ES2032582T3 (es) Procedimiento para preparar derivados de la oxima del 1,2,5,6,-tetrahidropiridin -3-carboxialdehido.
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ES2036533T3 (es) Derivados de 1,6-naftiridina, procedimientos para su obtencion y de medicamentos que los contienen para el tratamiento de enfermedades de los vasos sanguineos.
AR012602A1 (es) Derivados de amidina, formulacion farmaceutica, uso de dichos derivados para la fabricacion de medicamentos y proceso para la preparacion de dichosderivados
ES2189108T3 (es) Nuevas oxazinas dissustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
ES2039284T3 (es) Un procedimiento para preparar derivados de la 1-benzoil-2-oxo-5-alcoxi-pirrolidina.
ES2056849T3 (es) Heteroalquilen-quinolinaminas condensadas, un procedimiento y productos intermedios para su preparacion y su uso como medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 299914

Country of ref document: ES